PHAR
USDPharming Group N.V. ADS each representing 10 ordinary shares
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$11.050
Kõrge
$11.140
Madal
$11.050
Maht
0.00M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
767.1M
Tööstusharu
Biotehnoloogia
Riik
Netherlands
Kauplemisstatistika
Keskmine maht
0.00M
Börs
NGM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Pharming Group reports first quarter 2025 financial results and provides business update
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated
Seotud aktsiad
XTNT
Xtant Medical Holdings Inc.
XOMAP
XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
ATHE
Alterity Therapeutics Limited American Depositary Shares
SMLR
Semler Scientific Inc.
NTRB
Nutriband Inc.
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.